Vanda Pharmaceuticals Inc. (VNDA) financial statements and ratios from SEC XBRL: revenue $216.10M (TTM), net margin -102.0%, revenue growth 8.7% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $216.10M |
| Net Margin | -102.0% |
| Revenue Growth (YoY) | 8.7% |
| EPS Growth (YoY) | 1033.3% |
| FCF Growth (YoY) | 579.8% |
| Price / Book | 1.13 |
| Price / Sales | 1.51 |
| FCF Yield | -67.3% |
| Altman Z-Score | -0.05 (distress) |
| Sector P/E (Healthcare) | 21.7 |
VNDA overview · VNDA earnings · VNDA KPIs · VNDA investor relations · VNDA ownership · VNDA peers · VNDA filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.